Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $1.27B | $693.4M | +83.41% |
Operating Income | $-252.87M | $-691.08M | +63.41% |
Net Income | $-245.03M | $-705.81M | +65.28% |
EPS (Basic) | $-1.41 | $-6.23 | +77.37% |
EPS (Diluted) | $-1.41 | $-6.23 | +77.37% |
R&D Expense | $172.92M | $149.32M | +15.80% |
SG&A Expense | $731.74M | $755.35M | -3.13% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $2.27B | $926.12M | +145.63% |
Current Assets | $1.17B | $667.6M | +74.83% |
Total Liabilities | $1.78B | $869.78M | +105.05% |
Current Liabilities | $372.39M | $291.07M | +27.94% |
Stockholders' Equity | $491.33M | $56.34M | +772.09% |
Cash & Equivalents | $604.79M | $340.95M | +77.38% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $-218.09M | $-189.04M | -15.36% |
Investing Cash Flow | $-398.36M | $-130.39M | -205.51% |
Financing Cash Flow | $884.12M | $494.33M | +78.85% |
Dividends Paid | $0 | $5.63M | -100.00% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Margin | -19.9% | -99.7% | +79.78% |
Net Margin | -19.3% | — | — |
ROE | -49.9% | — | — |
ROA | -10.8% | — | — |
Current Ratio | $3.134 | — | — |
Debt to Equity | $3.63 | — | — |
TEM significantly increased its revenue by 83.4% in 2025, but continues to face substantial net losses and negative cash flows.
TEM's revenue surged by 83.4% year-over-year, driven by increased market penetration and product demand.
Source: Source: 10-K Income Statement, p.1
The operating margin improved from -99.7% to -19.9%, indicating better cost management despite ongoing losses.
Source: Source: 10-K Income Statement, p.1
R&D expenses rose by 15.8%, reflecting TEM's focus on innovation and product development.
Source: Source: 10-K Income Statement, p.1
TEM's debt to equity ratio of 3.63 indicates significant leverage, which could pose financial risks if revenue growth slows.
Source: Source: 10-K Balance Sheet, p.1
Unlock 2 more detailed risk analysis
Upgrade to unlockOther companies in Life Sciences Tools & Services